宫状瘤化疗前的新辅助免疫检查点阻塞 (GINECO机会窗口COLIBRI研究):第二阶段试验试验
Isabelle Ray-Coquard1, Marie-Christine Kaminsky-Forrett2, Ryotaro Ohkuma3,4
1GINECO, Centre Léon Bérard, and Université Claude Bernard Lyon 1, Lyon, France. isabelle.ray-coquard@lyon.unicancer.fr.
Nature communications
|January 6, 2026
概括
诱导免疫疗法与化学辐射相结合,显著增强了免疫细胞,并改善了晚期宫癌的治疗反应. 这种方法主要是瘤,导致高的完整反应率.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 临床试验 临床试验
背景情况:
- 将免疫疗法与化疗辐射结合起来,对局部发达的宫癌显示出有前途.
- 诱导组合免疫治疗对免疫调节和治疗结果的影响需要进一步研究.
研究的目的:
- 评估诱导组合免疫疗法 (nivolumab-plus-ipilimumab) 对局部晚期宫癌免疫调节和治疗反应的影响.
主要方法:
- 一项II期试验 (NCT04256213) 涉及40名患有局部晚期宫癌的女性患者.
- 患者在标准化疗前接受了一轮尼沃卢马布加伊皮利穆马布治疗,随后接受维护尼沃卢马布治疗.
- 多重免疫光组织成像用于评估免疫细胞的变化和HOT评分.
主要成果:
- 一个组合免疫治疗周期显著增加了CD8+/FOXP3+细胞比率和增殖CD8+T细胞密度.
- 免疫活性瘤的27基因签名HOT得分也显著增加.
- 免疫治疗后的客观反应率为13%,化学辐射后为98% (65%的完整反应),治疗结束时为90%.
结论:
- 诱导组合免疫疗法在局部发达的宫癌中有效调节瘤免疫微环境.
- 观察到的免疫变化和高基线HOT得分与完整的治疗反应相关.
- 诱导免疫疗法可以增强瘤原始化,从而改善对随后的标准治疗的反应.
相关概念视频
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
564
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
564
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
594
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
594